Deepak Poduval
Associate Research ScientistCards
About
Research
Publications
2025
Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC).
Tang C, Poduval D, Lee S, Panian J, Pandya C, Saidian A, McKay R, Braun D. Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16507.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaICI responseLoss of heterozygosityPrimary RCC tumorsPrimary tumorHLA evolutionary divergenceGene set enrichment analysisPost-treatment samplesRCC tumorsTumors resistant to immune checkpoint inhibitorsResistance to immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsResponse to ICI therapyAdvanced renal cell carcinomaImmune responseClear cell renal cell carcinomaSignatures of immune responsesCaris Life SciencesCell renal cell carcinomaPre-treatment tumorsSingle-sample gene set enrichment analysisDriver gene mutationsFisher's exact testMetabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Saliby R, Labaki C, Jammihal T, Soulati H, Gallegos J, Peris A, McCurry D, Shah V, Poduval D, El Zarif T, El Ahmar N, Nabil Laimon Y, Bagheri Sheshdeh A, Eid M, Krajewski K, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Journal Of Clinical Oncology 2025, 43: 571-571. DOI: 10.1200/jco.2025.43.5_suppl.571.Peer-Reviewed Original ResearchProgression-free survivalImmune checkpoint inhibitorsRenal cell carcinomaComplete responsePartial responseProgressive diseaseWhole-exome sequencingMetabolic gene signatureOverall survivalVEGF inhibitorsCell carcinomaGene set enrichment analysisER patientsSignature scorePatients treated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitionResponse to ICIExceptional responseAdvanced clear cell renal cell carcinomaProgression-free survival predictorsProlonged progression-free survivalMetastatic renal cell carcinomaMultivariate Cox proportional hazards analysisGene signaturePhase III clinical trialsImmunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon Y, Eid M, Sheshdeh A, Krajewski K, Büttner F, Schwab M, Heng D, Casellas R, Rai K, Zacharias Millward N, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri T, Braun D, Shukla S. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nature Cancer 2025, 6: 372-384. PMID: 39789182, PMCID: PMC12121501, DOI: 10.1038/s43018-024-00896-w.Peer-Reviewed Original ResearchConceptsTertiary lymphoid structuresVascular endothelial growth factorRenal cell carcinomaCell carcinomaCytotoxic T-lymphocyte-associated protein 4 inhibitorsResponse to immune checkpoint inhibitionExceptional responseMetastatic clear cell renal cell carcinomaStandard-of-care immunotherapiesTertiary lymphoid structure formationCytotoxic T cell responsesClear cell renal cell carcinomaIO-based treatmentsTreatment-naive personsImmune checkpoint inhibitionImmune checkpoint inhibitorsCell renal cell carcinomaT cell responsesT-cell-directedEndothelial growth factorCell death proteinAntitumor immunityCheckpoint inhibitionCheckpoint inhibitorsNeoantigen load
2024
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.Peer-Reviewed Original ResearchGenomic transcription factor binding site selection is edited by the chromatin remodeling factor CHD4
Saotome M, Poduval D, Grimm S, Nagornyuk A, Gunarathna S, Shimbo T, Wade P, Takaku M. Genomic transcription factor binding site selection is edited by the chromatin remodeling factor CHD4. Nucleic Acids Research 2024, 52: 3607-3622. PMID: 38281186, PMCID: PMC11039999, DOI: 10.1093/nar/gkae025.Peer-Reviewed Original ResearchConceptsTranscription factorsBreast cancer cellsBinding motifTranscription factor binding motifsTranscription factor-DNA interactionsLineage-determining transcription factorsCellular reprogrammingProof-reading enzymeBasal breast cancer cellsChromatin-binding activityCancer cellsBinding site selectionEukaryotic genomesNucleosome positioningChromatin accessibilityChromatin openingGene activationCHD4Gene expressionChromatinTranscriptionBinding activityFrequent mutationsUnoccupied sitesExquisite specificity
2022
GATA3 Truncation Mutants Alter EMT Related Gene Expression via Partial Motif Recognition in Luminal Breast Cancer Cells
Saotome M, Poduval D, Nair R, Cooper M, Takaku M. GATA3 Truncation Mutants Alter EMT Related Gene Expression via Partial Motif Recognition in Luminal Breast Cancer Cells. Frontiers In Genetics 2022, 13: 820532. PMID: 35154280, PMCID: PMC8831884, DOI: 10.3389/fgene.2022.820532.Peer-Reviewed Original ResearchMutant cell linesEpithelial-to-mesenchymal transitionCell linesGATA3 mutationsSplice site deletionLuminal breast cancer cell linesLuminal breast cancer cellsGene expression patternsMutant-expressing cellsBreast cancer cell linesMotif enrichmentChromatin localizationBreast cancer cellsMotif recognitionTruncation mutantsCancer cell linesSite deletionTranscriptome analysisTruncating mutationsBreast cancer developmentBreast cancer patientsBreast cancer characterizationRelated gene expressionMutated genesGene expression
2021
Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
Poduval D, Sichmanova Z, Straume A, Lønning P, Knappskog S. Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer. PLOS ONE 2021, 16: e0253361. PMID: 34111221, PMCID: PMC8191967, DOI: 10.1371/journal.pone.0253361.Peer-Reviewed Original Research
2020
Assessment of tumor suppressor promoter methylation in healthy individuals
Poduval D, Ognedal E, Sichmanova Z, Valen E, Iversen G, Minsaas L, Lønning P, Knappskog S. Assessment of tumor suppressor promoter methylation in healthy individuals. Clinical Epigenetics 2020, 12: 131. PMID: 32859265, PMCID: PMC7455917, DOI: 10.1186/s13148-020-00920-7.Peer-Reviewed Original ResearchThe novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
Poduval D, Sichmanova Z, Straume A, Lønning P, Knappskog S. The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer. PLOS ONE 2020, 15: e0225357. PMID: 32298266, PMCID: PMC7162276, DOI: 10.1371/journal.pone.0225357.Peer-Reviewed Original Research
2018
Patterns of genomic evolution in advanced melanoma
Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda L, Hovig E, Myklebost O, Knappskog S, Lønning P. Patterns of genomic evolution in advanced melanoma. Nature Communications 2018, 9: 2665. PMID: 29991680, PMCID: PMC6039447, DOI: 10.1038/s41467-018-05063-1.Peer-Reviewed Original Research